ANI Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Minnesota, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
210 W Main St, Baudette, Minnesota, 5662...Phone Number
(218) 634-3500Website
www.anipharmaceuticals.comRevenue
$923.7 MillionStock Symbol
ANIPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
7
1
2
1
2
1
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities.Explore more
ANI Pharmaceuticals Org Chart
SS
Head Chief Operating Officer, Research Develo...
MS
Head Chief Operating Officer, Research Develo...
MS
Head of Research & Development & Chief Operat...
KD
Senior Vice President, Chief Human Resources ...
MP
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ANI Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ANI Pharmaceuticals recently announced quarterly report
Check if ANI Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if ANI Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ANI Pharmaceuticals
Product Launch: Get notified when ANI Pharmaceuticals launches new products
Funding: Get notified immidiatlly once ANI Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
ANI Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ANI Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at ANI Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to ANI Pharmaceuticals
Compare insights from companies similar to ANI Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ANI Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ANI Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ANI Pharmaceuticals.
ANI Pharmaceuticals financials insights
Gather financial insights about ANI Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Share Placement
$125M
2024
Debt
$280M
ANI Pharmaceuticals Tech Stack
A closer look at the technologies used by ANI Pharmaceuticals
See more technologies
Most Recent Scoops
Earnings
ANI Pharmaceuticals has reported Cortrophin revenue guidance of $540 to $575 million for fiscal year 2026, with Q1 performance of $75 million and implied Q2 guidance of approximately $118 to $128 million.
Earnings, Finance
Earnings
ANI Pharmaceuticals has reported that H2 2025 accounted for approximately 61% of annual Cortrophin sales, following a similar H1 sales force expansion, with the combined ACTH market expected to grow approximately 30% based on combined guidance from both market participants.
Sales
Hiring Plans
ANI Pharmaceuticals has announced plans to deploy a new 64-person sales force targeting approximately 7,000 primary care physicians and podiatrists for Cortrophin as a treatment option for patients with severe acute gouty arthritis flares, representing a 50% expansion of the field force, with approximately 80% of the team recruited, trained, and in the field by May and the remainder rolling out by June.
Hiring Plans, Sales, Recruitment, Doctors / Physicians, Field /Outside Sales, HR Operations, Sales Training
Hiring Plans
ANI Pharmaceuticals has more open roles in Operations than it has had at any time in the past 6 months.
Hiring Plans
Person-Based
Award
ANI Pharmaceuticals News & Media
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology under the 2010 Agreement between the parties.ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRONICITY clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
Carey exercised vested options under a pre-established Rule 10b5-1 trading plan adopted in March, retaining 177,543 directly held shares.ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ANI Pharmaceuticals
Sign Up For FreeTo access detailed company insights
ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics... Read More
